Some QOL benefits for second-line Halaven in breast cancer
This article was originally published in Scrip
Eisai has presented new quality of life (QOL) data from one of the main Phase III trials with its breast cancer drug Halaven (eribulin mesylate) that it will be hoping may boost the competitive position of the novel microtubule dynamics inhibitor in the earlier line treatment of metastatic disease.
You may also be interested in...
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.